See more : Investin – K Invest Globale Aktier II (WEIBGA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Revvity, Inc. (RVTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Dazzle Fashion Co., Ltd (603587.SS) Income Statement Analysis – Financial Results
- SRT Marine Systems plc (SRT.L) Income Statement Analysis – Financial Results
- Thai Mui Corporation Public Company Limited (THMUI.BK) Income Statement Analysis – Financial Results
- Vision Hydrogen Corporation (VIHD) Income Statement Analysis – Financial Results
- Ivanhoe Capital Acquisition Corp. (IVAN) Income Statement Analysis – Financial Results
Revvity, Inc. (RVTY)
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.75B | 3.31B | 5.07B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.26B | 2.24B | 2.17B | 2.12B | 1.92B | 1.70B | 1.81B | 1.94B | 1.79B | 1.55B | 1.47B | 1.69B | 1.54B | 1.50B | 1.33B | 1.70B | 1.36B | 1.41B | 1.46B | 1.43B | 1.42B | 1.33B | 2.70B | 2.79B | 2.69B | 2.47B | 1.65B | 1.41B | 1.24B | 1.15B | 1.16B |
| Cost of Revenue | 1.21B | 1.32B | 2.22B | 1.67B | 1.49B | 1.44B | 1.18B | 1.10B | 1.24B | 1.23B | 1.19B | 1.15B | 1.07B | 945.72M | 1.03B | 1.11B | 1.06B | 918.29M | 859.30M | 1.01B | 906.27M | 904.10M | 721.73M | 918.43M | 787.30M | 991.30M | 1.04B | 1.01B | 1.01B | 957.80M | 2.30B | 2.39B | 2.31B | 2.14B | 1.35B | 1.11B | 984.00M | 935.30M | 927.90M |
| Gross Profit | 1.54B | 1.99B | 2.85B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B | 1.02B | 1.00B | 976.97M | 963.21M | 850.58M | 758.63M | 779.79M | 830.11M | 724.74M | 628.07M | 614.54M | 680.55M | 628.95M | 600.88M | 608.33M | 776.84M | 575.80M | 416.60M | 420.70M | 419.50M | 407.00M | 374.80M | 393.20M | 401.50M | 382.00M | 333.50M | 303.80M | 292.00M | 251.90M | 209.80M | 227.20M |
| Gross Profit Ratio | 55.98% | 60.08% | 56.27% | 55.78% | 48.41% | 48.27% | 47.54% | 47.90% | 45.28% | 44.90% | 45.10% | 45.54% | 44.27% | 44.51% | 43.03% | 42.84% | 40.55% | 40.62% | 41.70% | 40.34% | 40.97% | 39.93% | 45.74% | 45.82% | 42.24% | 29.59% | 28.80% | 29.39% | 28.67% | 28.13% | 14.57% | 14.40% | 14.21% | 13.48% | 18.41% | 20.76% | 20.38% | 18.32% | 19.67% |
| Research & Development | 216.58M | 221.62M | 274.97M | 205.39M | 189.34M | 194.00M | 139.40M | 124.28M | 125.93M | 121.14M | 133.02M | 132.64M | 115.82M | 95.41M | 107.25M | 108.06M | 111.62M | 99.72M | 87.37M | 87.05M | 83.15M | 86.45M | 81.32M | 86.12M | 71.20M | 46.00M | 44.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.02B | 1.03B | 1.23B | 917.89M | 815.32M | 811.91M | 616.17M | 600.89M | 598.85M | 659.34M | 585.85M | 632.73M | 628.60M | 490.66M | 504.70M | 522.88M | 444.41M | 376.85M | 365.46M | 387.54M | 386.40M | 431.30M | 411.15M | 418.98M | 327.10M | 226.30M | 243.40M | 290.90M | 284.90M | 278.20M | 234.60M | 242.00M | 223.10M | 195.90M | 179.90M | 169.30M | 151.40M | 133.20M | 130.10M |
| Other Expenses | 0.00 | 25.26M | 36.41M | -23.52M | -27.69M | -13.21M | 33.59M | -3.73M | -4.80M | -5.54M | -14.84M | -2.92M | -3.88M | -2.14M | 0.00 | 0.00 | -15.35M | 1.74M | -1.50M | 28.89M | 25.67M | 23.11M | 0.00 | 87.72M | 66.10M | 50.40M | 44.60M | 40.90M | 39.40M | 36.80M | 37.80M | 36.30M | 33.70M | 29.90M | 25.50M | 24.60M | 21.20M | 16.40M | 15.10M |
| Operating Expenses | 1.24B | 1.25B | 1.50B | 1.12B | 1.00B | 1.01B | 755.57M | 725.16M | 724.78M | 780.48M | 718.87M | 765.37M | 744.42M | 586.07M | 611.95M | 630.95M | 540.69M | 478.31M | 451.33M | 503.48M | 495.22M | 540.87M | 492.46M | 592.81M | 464.40M | 322.70M | 332.90M | 331.80M | 324.30M | 315.00M | 272.40M | 278.30M | 256.80M | 225.80M | 205.40M | 193.90M | 172.60M | 149.60M | 145.20M |
| Cost & Expenses | 2.45B | 2.57B | 3.72B | 2.80B | 2.49B | 2.44B | 1.94B | 1.83B | 1.96B | 2.01B | 1.91B | 1.92B | 1.82B | 1.53B | 1.64B | 1.74B | 1.60B | 1.40B | 1.31B | 1.51B | 1.40B | 1.44B | 1.21B | 1.51B | 1.25B | 1.31B | 1.37B | 1.34B | 1.34B | 1.27B | 2.58B | 2.67B | 2.56B | 2.37B | 1.55B | 1.31B | 1.16B | 1.08B | 1.07B |
| Interest Income | 72.13M | 3.59M | 2.24M | 1.01M | 1.50M | 1.14M | 2.57M | 702.00K | 673.00K | 667.00K | 650.00K | 747.00K | 1.88M | 832.00K | 1.04M | 4.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 98.81M | 103.96M | 102.13M | 49.71M | 63.63M | 66.98M | 43.94M | 41.53M | 38.00M | 36.27M | 49.92M | 45.79M | 24.78M | 15.89M | 17.16M | 82.14M | 41.70M | 0.00 | 0.00 | 47.71M | 105.08M | 279.72M | 128.31M | 74.63M | 7.00M | 0.00 | 64.60M | 8.90M | 0.00 | 121.80M | 12.10M | 0.00 | 900.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 431.77M | 427.00M | 311.44M | 246.51M | 214.03M | 180.59M | 105.00M | 99.97M | 121.48M | 125.26M | 154.94M | 126.87M | 129.26M | 108.96M | 113.11M | 125.10M | 103.50M | 66.84M | 124.38M | 89.51M | 89.78M | 96.11M | 84.26M | 127.26M | 66.10M | 50.40M | 44.60M | 48.20M | 36.00M | 36.80M | 30.50M | 31.10M | 29.70M | 19.90M | 15.00M | 17.70M | 12.20M | 16.40M | 15.10M |
| EBITDA | 713.56M | 1.30B | 1.73B | 1.20B | 609.55M | 518.76M | 424.63M | 405.96M | 378.63M | 322.61M | 331.73M | 223.24M | 200.06M | 267.04M | 200.91M | 262.65M | 264.89M | 219.24M | 287.59M | 266.58M | 223.51M | 156.13M | 200.13M | 311.28M | 177.50M | 82.10M | 166.20M | 135.90M | 118.70M | 168.00M | 151.30M | 154.30M | 154.90M | 127.60M | 113.40M | 115.80M | 91.50M | 57.20M | 79.00M |
| EBITDA Ratio | 25.94% | 36.19% | 34.45% | 32.00% | 20.09% | 18.13% | 20.32% | 18.21% | 18.02% | 15.02% | 17.19% | 15.25% | 11.40% | 15.41% | 14.39% | 16.42% | 15.20% | 14.24% | 24.34% | 15.80% | 17.83% | 14.58% | 21.19% | 18.36% | 17.89% | 5.83% | 11.38% | 9.52% | 8.36% | 12.61% | 5.61% | 5.53% | 5.76% | 5.16% | 6.87% | 8.23% | 7.40% | 5.00% | 6.84% |
| Operating Income | 300.56M | 742.70M | 1.33B | 978.58M | 361.97M | 323.88M | 304.80M | 283.07M | 286.13M | 210.74M | 217.44M | 195.66M | 89.70M | 153.60M | 147.61M | 192.97M | 168.17M | 153.40M | 234.29M | 177.07M | 183.91M | 123.37M | 197.58M | 184.03M | 104.40M | 31.70M | 121.60M | 87.70M | 82.70M | 131.20M | 120.80M | 123.20M | 125.20M | 107.70M | 98.40M | 98.10M | 79.30M | 40.80M | 63.90M |
| Operating Income Ratio | 10.93% | 22.43% | 26.29% | 25.87% | 12.55% | 11.66% | 13.50% | 13.38% | 12.65% | 9.42% | 10.04% | 9.25% | 4.67% | 9.01% | 8.15% | 9.96% | 9.41% | 9.92% | 15.90% | 10.49% | 11.98% | 8.20% | 14.86% | 10.86% | 7.66% | 2.25% | 8.32% | 6.14% | 5.83% | 9.85% | 4.48% | 4.42% | 4.66% | 4.35% | 5.96% | 6.98% | 6.42% | 3.56% | 5.53% |
| Total Other Income/Expenses | -117.59M | -90.86M | -54.88M | 39.09M | -124.83M | -66.20M | 1.10M | -50.51M | -42.12M | 4.60M | -53.76M | -140.50M | -26.77M | -10.78M | -15.79M | -45.61M | -16.88M | -2.67M | -74.29M | -38.33M | -56.39M | -32.87M | -163.43M | -39.54M | -66.50M | 124.30M | -35.80M | -7.30M | 3.40M | -76.90M | 1.10M | -2.10M | -4.90M | -500.00K | 1.40M | -700.00K | 1.70M | 31.50M | 24.70M |
| Income Before Tax | 182.98M | 651.84M | 1.28B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 244.02M | 169.60M | 153.33M | 50.59M | 62.93M | 161.98M | 130.68M | 147.36M | 151.29M | 150.74M | 66.66M | 136.75M | 80.88M | -8.55M | 34.15M | 144.49M | 44.90M | 156.00M | 54.00M | 80.40M | 86.10M | -17.10M | 121.90M | 121.10M | 120.30M | 107.20M | 99.80M | 97.40M | 81.00M | 72.30M | 88.60M |
| Income Before Tax Ratio | 6.65% | 19.68% | 25.26% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 10.79% | 7.58% | 7.08% | 2.39% | 3.28% | 9.50% | 7.21% | 7.61% | 8.46% | 9.75% | 4.52% | 8.10% | 5.27% | -0.57% | 2.57% | 8.52% | 3.29% | 11.08% | 3.70% | 5.63% | 6.07% | -1.28% | 4.52% | 4.34% | 4.47% | 4.33% | 6.05% | 6.93% | 6.55% | 6.31% | 7.67% |
| Income Tax Expense | 3.47M | 129.16M | 347.60M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 31.33M | 8.44M | -12.19M | -17.85M | 62.75M | 26.06M | 37.93M | 21.22M | 17.46M | 32.41M | 128.00K | 38.50M | 25.87M | -4.42M | 34.77M | 58.42M | 16.50M | 54.00M | 23.40M | 25.90M | 31.80M | 15.00M | 42.30M | 33.30M | 39.10M | 33.20M | 29.90M | 28.70M | 25.50M | 27.40M | 32.90M |
| Net Income | 693.09M | 569.18M | 943.16M | 727.89M | 227.56M | 237.93M | 156.89M | 234.30M | 212.43M | 157.78M | 167.21M | 69.94M | 174.00K | 135.92M | 85.60M | 126.41M | 131.69M | 119.58M | 66.53M | 96.04M | 52.96M | -4.14M | -620.00K | 90.52M | 28.40M | 102.00M | 33.70M | 60.20M | 54.30M | -32.10M | 79.60M | 87.80M | 81.20M | 74.00M | 69.90M | 68.70M | 55.50M | 44.90M | 55.70M |
| Net Income Ratio | 25.20% | 17.19% | 18.61% | 19.24% | 7.89% | 8.56% | 6.95% | 11.08% | 9.39% | 7.05% | 7.72% | 3.31% | 0.01% | 7.98% | 4.72% | 6.52% | 7.37% | 7.73% | 4.51% | 5.69% | 3.45% | -0.27% | -0.05% | 5.34% | 2.08% | 7.24% | 2.31% | 4.22% | 3.83% | -2.41% | 2.95% | 3.15% | 3.02% | 2.99% | 4.24% | 4.89% | 4.49% | 3.92% | 4.82% |
| EPS | 5.56 | 4.51 | 8.12 | 6.53 | 2.05 | 2.15 | 1.43 | 2.14 | 1.89 | 1.40 | 1.49 | 0.61 | 0.00 | 1.16 | 0.74 | 1.07 | 1.11 | 0.96 | 0.51 | 0.75 | 0.42 | -0.03 | -0.01 | 0.92 | 0.31 | 1.13 | 0.37 | 0.64 | 0.53 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| EPS Diluted | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 1.42 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.00 | 1.15 | 0.73 | 1.07 | 1.09 | 0.95 | 0.51 | 0.74 | 0.41 | -0.03 | -0.01 | 0.89 | 0.31 | 1.11 | 0.37 | 0.64 | 0.51 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| Weighted Avg Shares Out | 124.70M | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 112.51M | 112.59M | 112.25M | 113.73M | 112.98M | 117.11M | 116.25M | 117.66M | 118.64M | 124.57M | 129.52M | 128.06M | 126.09M | 125.57M | 104.56M | 98.39M | 91.30M | 90.27M | 91.08M | 94.80M | 103.03M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
| Weighted Avg Shares Out (Dil) | 124.81M | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M | 113.86M | 117.98M | 116.59M | 118.69M | 120.81M | 125.88M | 131.43M | 129.79M | 129.17M | 125.57M | 107.83M | 101.71M | 91.30M | 91.89M | 91.08M | 94.80M | 105.98M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work...
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
Revitty (RVTY) Q3 2024 Earnings Call Transcript
Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations...
Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.
Revvity cuts 2024 revenue forecast amid biotech spending slowdown
Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.
Revvity Announces Financial Results for the Third Quarter of 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue...
Revvity to Report Q3 Earnings: What's in Store for the Stock?
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
Source: https://incomestatements.info
Category: Stock Reports